Corcept Cash Ratio from 2010 to 2024

CORT Stock  USD 52.42  2.72  4.93%   
Corcept Therapeutics Cash Ratio yearly trend continues to be comparatively stable with very little volatility. Cash Ratio will likely drop to 1.23 in 2024. From the period from 2010 to 2024, Corcept Therapeutics Cash Ratio quarterly data regression had r-value of  0.20 and coefficient of variation of  144.01. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
1.29707669
Current Value
1.23
Quarterly Volatility
15.12152825
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Corcept Therapeutics Correlation against competitors.

Latest Corcept Therapeutics' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Corcept Therapeutics Incorporated over the last few years. It is Corcept Therapeutics' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Pretty Stable
   Cash Ratio   
       Timeline  

Corcept Cash Ratio Regression Statistics

Arithmetic Mean10.50
Geometric Mean5.29
Coefficient Of Variation144.01
Mean Deviation9.79
Median5.35
Standard Deviation15.12
Sample Variance228.66
Range47.382
R-Value0.20
Mean Square Error235.97
R-Squared0.04
Significance0.47
Slope0.69
Total Sum of Squares3,201

Corcept Cash Ratio History

2024 1.23
2023 1.3
2022 5.35
2021 48.61
2020 45.19
2019 7.67
2018 5.77

About Corcept Therapeutics Financial Statements

Corcept Therapeutics shareholders use historical fundamental indicators, such as Cash Ratio, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Ratio 1.30  1.23 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.